Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980484 | 0.91 | GPR119 (0.45) | GPR119MCHR1KCNH2HTR2CNPC1 | |
| SCHEMBL3981515 | 0.87 | GPR119 (0.57) | GPR119 | |
| SCHEMBL3983238 | 0.87 | GPR119 (0.64) | GPR119 | |
| SCHEMBL3980193 | 0.84 | GPR119 (0.50) | GPR119KCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3984237 | 0.84 | GPR119 (0.39) | GPR119MCHR1KCNH2HTR2CNPC1 | |
| SCHEMBL3981182 | 0.84 | GPR119 (0.42) | GPR119MCHR1KCNH2HTR2CNPC1 | |
| SCHEMBL3985778 | 0.82 | NPC1 (0.42) | GPR119MCHR1KCNH2HTR2CNPC1 | |
| SCHEMBL3983937 | 0.81 | GPR119 (0.47) | GPR119KCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14190997 | 0.80 | GPR119 (0.47) | GPR119MCHR1KCNH2HTR2CNPC1 | |
| SCHEMBL4050800 | 0.79 | ALDH1A1 (0.41) | GPR119MCHR1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885MCHR1 108/4885KCNH2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.